

Safety Related Changes

Afinitor (**everolimus**) is now indicated in postmenopausal women with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2) negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.

Isentress (**raltegravir**) in combination with other antiretroviral agents is now indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adolescents and children from the age of 2 years.

Neupro (**rotigotine**) is no longer indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.